Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Blackfinch Investments (Fund)
Blackfinch Ventures EIS Portfolios
2nd Dec 2024
Calculus Capital (Funds)
Calculus Knowledge Intensive EIS Fund 3
29th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
108: An all-star panel discuss EIS & VCTs in 2024 and look forward to 2025
Stay up-to-date with the latest research
Sign up to our newsletter
Latest Update
Our research can be accessed for free under MIFID.
Find out more >
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Infrastructure
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Renewables
Services
Technology
Transportation
Utilities
list companies
Oxford BioMedica
Life Sciences
De-leveraging the balance sheet
18 Jun 2019
Non-Standard Finance
Financials
Back to basics
By
Mark Thomas
17 Jun 2019
Stay up-to-date with the latest research
Sign up to our newsletter
Chamberlin Plc
Industrial
Trading remains difficult; forecasts lowered
By
Paul Singer
04 Jun 2019
Morses Club Plc
Financials
Steady, reliable core, growth in new business lines
By
Mark Thomas
03 Jun 2019
City of London Investment Group
Financials
Market bounce gives FUM bounce
By
Dr Brian Moretta
17 Apr 2019
Advanced Oncotherapy
Life Sciences
Preparing for commercialisation
By
Dr Martin Hall
16 Apr 2019
ValiRx
Life Sciences
VAL401 is going forward
By
Dr Martin Hall
15 Apr 2019
Tissue Regenix
Life Sciences
Expanded GPO coverage secured
By
Dr Martin Hall
10 Apr 2019
genedrive Plc
Life Sciences
First commercial sales in new focus area: bio-threats
08 Apr 2019
Non-Standard Finance
Financials
Reading the runes: strong, controlled growth
By
Mark Thomas
05 Dec 2018
Redx Pharma
Life Sciences
RXC006: first anti-fibrosis development candidate
By
Dr Martin Hall
30 Nov 2018
Prev
1
...
16
17
18
19
20
...
30
Next
